Date: 2011-01-05
Type of information: Licensing agreement
Compound: production cell line expressing Neogenix NPC-1C
Company: Selexis (Switzerland) Neogenix Oncology (USA)
Therapeutic area:
Type agreement: licensing
commercialisation
Action mechanism:
Disease:
Details: Selexis, a Swiss-based biotechnology company offering technologies and services to enable improved drug discovery, development, and cGMP production, and Neogenix Oncology have entered into a commercial license agreement to commercialize the high expression production cell line expressing Neogenix NPC- 1C. Selexis had previously developed the high expression NPC-1C cell line for Neogenix under a Contract Cell Line Development Services Agreement. Terms of the agreement were not disclosed.
Financial terms:
Latest news:
